EU Health Group Adopts New Tech Guidance
The Member State Coordination Group on Health Technology Assessment has updated its procedural framework for health evaluations.
Updated on Oct. 27, 2026 in Biotech
Live Poll
Does allowing observers at scientific health consultations improve public trust in the approval process?
The Member State Coordination Group on Health Technology Assessment (HTACG) has adopted two updated procedural guidance documents covering medicines, medical devices, and in vitro diagnostic tests. These rules introduce a new watcher role for joint scientific consultations.
Why it matters
The new guidelines aim to streamline the evaluation of health technologies by clarifying the roles of various stakeholders and expert bodies during the assessment process. This update provides a structured framework for managing consultations involving the European Medicines Agency and specialized expert panels.
The consultation procedure for health technologies is designed to last 4.5 months, with requests receiving a formal response within 15 working days following the close of the submission period.
The players
Member State Coordination Group on Health Technology Assessment
This body coordinates health technology assessments across the European Union to ensure consistent evaluation standards.
European Commission
This is the executive branch of the European Union responsible for proposing legislation and implementing decisions.
European Medicines Agency
This agency is responsible for the scientific evaluation, supervision, and safety monitoring of medicines in the European Union.
The details
The newly introduced watcher role permits subgroup representatives to attend meetings between an assessor and co-assessor in an observational capacity. To serve as a watcher, representatives must apply at the start of the consultation process, with the final number of permitted observers determined by the assigned assessors.
Timeline
The HTACG adopted the updated procedural guidance documents on 22 October 2026.
The European Commission announced the publication of the documents on 26 October 2026.
The Tech Race
These guidelines extend the regulatory architecture established by the European Union Health Technology Assessment Regulation. By integrating a formal watcher role, the update refines the EU's approach to coordinating complex medical assessments against the backdrop of rapid biotech innovation.
The new guidance allows for greater transparency in the evaluation of medical devices and medicines by enabling subgroup representatives to observe high-level technical consultations. These procedural changes help ensure that various expert panels and stakeholders have a defined path to monitor the assessment of new diagnostic tests.
The takeaway
Transparency in health technology assessment is evolving through the inclusion of observer roles in technical meetings. Stakeholders interested in medical device evaluations should note the requirement to apply for the watcher role at the beginning of the consultation cycle.
Further reading
For broader context on European medical evaluation standards, visit our Biotech section.
More information
View the full procedural guidance documents for complete details on the new consultation framework.
Live Poll
Does allowing observers at scientific health consultations improve public trust in the approval process?
